A Phase 1/2 interventional study of SHR-A1811 and Adebelimab injection in Recurrent or Metastatic Cervical Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-06.
Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.
Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 163rd largest by planned enrollment of the 360 interventional ones that give a count, is one of 44 that started in 2025, is one of 26 in phase 1/2, reaches primary completion later than 124 of the 239 other live ones, and was the 392nd registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 17–75 · Women only
Catherin Zhang · Sites in China
Ages 18–75 · Women only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80 · Women only
Manni Huang · Sites in China
Ages 18–75 · Women only
Sun Yat-sen University · Sites in China
Ages 18–70 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
455 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 78 · Phase 2 174 · Phase 3 67 · Phase 4 6
First in 2005; this study’s year is marked. 44 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 90 across the 360 interventional studies, 460 across the 95 observational. Of the 87 that completed or were terminated, 12 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 455 have an industry lead sponsor. The 10 most frequent:
This study is registered under Suzhou Suncadia Biopharmaceuticals Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 9 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
53 of the studies in Uterine Cervical Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06459687Phase 3Lee's Pharmaceutical LimitedPhase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer | 2027-09-01 |
| NCT04422366Phase 3Shanghai Bovax Biotechnology Co., Ltd.Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | 2027-09-15 |
| NCT06079671Phase 3AstraZenecaStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | 2027-11-26 |
| NCT06416696Cancer Institute and Hospital, Chinese Academy of Medical SciencesToripalimab for High-risk Locally Advanced Cervical Cancer | 2026-12 |
| NCT07860203Catherin ZhangStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | 2026-12 |
Add all 53 to your calendar (.ics) → With an account.
Among the 455 studies in Uterine Cervical Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.
Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection
Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection · Drug: SHR-8068
Drug: SHR-A1811 · Drug: Adebelimab injection · Drug: Bevacizumab injection · Drug: SHR-8068 · Drug: Cisplatin injection · Drug: Carboplatin injection
Grade≥3 drug-related adverse events (TRAEs).
Time frame: Up to 3 years.
Grade≥3 drug-related serious adverse events (TRAEs).
Time frame: Up to 3 years.
Objective response rate (ORR).
Time frame: Up to 3 years.
Duration of response (DOR).
Time frame: Up to 3 years.
Disease control rate (DCR).
Time frame: Up to 3 years.
Progression-free survival (PFS).
Time frame: Up to 3 years.
Overall survival (OS).
Time frame: Up to 3 years.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 18 months after the start.
Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's planned 18 months is below that.
Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab rezetecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd. →